Company intelligence / Profile preview

Next Med

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

NextMed is a healthcare technology company that operates a comprehensive telemedicine platform primarily focused on weight management and metabolic health. The company facilitates patient access to licensed medical providers who specialize in prescribing GLP-1 receptor agonists, such as semaglutide and tirzepatide, for chronic weight management. Beyond weight loss, NextMed provides services for hormone therapy, lab testing, and general wellness through a subscription-based model. The platform integrates clinical oversight with digital health tools to monitor patient progress and optimize treatment outcomes.

Therapeutic areas: Endocrinology
Modalities: Small moleculePeptides
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on Next Med.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Next Med.

Explore the full profile